No connection

Search Results

ANIK vs MENS

ANIK
Anika Therapeutics, Inc.
BEARISH
Price
$14.20
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
85%
MENS
Jyong Biotech Ltd.
BEARISH
Price
$2.79
Market Cap
$212.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ANIK
--
MENS
--
Forward P/E
ANIK
35.5
MENS
--
P/B Ratio
ANIK
1.37
MENS
-8.91
P/S Ratio
ANIK
1.82
MENS
--
EV/EBITDA
ANIK
-29.07
MENS
-121.13

Profitability

Gross Margin
ANIK
56.56%
MENS
0.0%
Operating Margin
ANIK
2.11%
MENS
0.0%
Profit Margin
ANIK
-9.64%
MENS
0.0%
ROE
ANIK
-6.71%
MENS
--
ROA
ANIK
-3.52%
MENS
-5.44%

Growth

Revenue Growth
ANIK
0.0%
MENS
--
Earnings Growth
ANIK
--
MENS
--

Financial Health

Debt/Equity
ANIK
0.18
MENS
--
Current Ratio
ANIK
4.72
MENS
0.62
Quick Ratio
ANIK
3.71
MENS
0.62

Dividends

Dividend Yield
ANIK
--
MENS
--
Payout Ratio
ANIK
0.0%
MENS
0.0%

AI Verdict

ANIK BEARISH

ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.

Strengths
High gross margin (56.56%) indicates strong pricing power and cost control in production
Strong liquidity position with current ratio of 4.72 and quick ratio of 3.71
Low debt-to-equity ratio (0.18) suggests conservative capital structure
Risks
Piotroski F-Score of 2/9 signals poor financial health and high distress risk
Negative net profit margin (-9.64%) and ROE (-6.71%) indicate unprofitable operations
Zero revenue growth (0% YoY) despite a growing market cap, suggesting stagnation
MENS BEARISH

MENS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a critical lack of fundamental value. The company reports a negative Price-to-Book ratio of -8.91, indicating negative shareholders' equity, and a Current Ratio of 0.62, signaling an immediate liquidity crisis. With zero reported revenue and a catastrophic 95% price decline over the last six months, the stock appears to be in a speculative death spiral. Recent short-term gains are likely volatility-driven 'dead cat bounces' rather than a fundamental recovery.

Strengths
Recent short-term price recovery (+40.9% in 1 month)
Small market cap allows for high volatility spikes
Operates in the high-growth Healthcare/Biotech sector
Risks
Negative book value indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.62)
Complete absence of revenue and profit margins

Compare Another Pair

ANIK vs MENS: Head-to-Head Comparison

This page compares Anika Therapeutics, Inc. (ANIK) and Jyong Biotech Ltd. (MENS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile